{"organizations": [], "uuid": "d21fc3a84f8f2a61cafc16f6b6679e7b1aabd33c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-us-fda-files-nda-under-priority-re/brief-u-s-fda-files-nda-under-priority-review-for-migalastat-idUSASB0C55S", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.06, "site_type": "news", "published": "2018-02-12T20:51:00.000+02:00", "replies_count": 0, "uuid": "d21fc3a84f8f2a61cafc16f6b6679e7b1aabd33c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-files-nda-under-priority-re/brief-u-s-fda-files-nda-under-priority-review-for-migalastat-idUSASB0C55S", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "amicus therapeutics inc", "sentiment": "negative"}, {"name": "fda files nda under priority review for migalastat", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 12, 2018 / 12:51 PM / in 8 minutes BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Amicus Therapeutics Inc: \n* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE \n* AMICUS THERAPEUTICS INC - PRESCRIPTION DRUG USER FEE ACT GOAL DATE FOR FDA DECISION IS AUGUST 13, 2018 Source text for Eikon: Further company coverage:", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T20:51:00.000+02:00", "crawled": "2018-02-12T14:59:23.040+02:00", "highlightTitle": ""}